Çelik Tekeli Merve, Yücel Çiğdem, Ünal Sedat, Aktaş Yeşim
Erciyes University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Kayseri, Turkey.
Turk J Pharm Sci. 2018 Apr;15(1):91-96. doi: 10.4274/tjps.70783. Epub 2018 Apr 2.
In recent years, studies on oral use have increased rapidly due to the restrictive aspects of parenteral administration of indispensable peptide-structured insulin in the rapidly growing worldwide treatment of diabetes. The aim of the study was to examine the development of a novel insulin-loaded LCS-NP complex, and its characterization and efficacy on pancreatic cells responsible for insulin release.
Blank liposomes and insulin-loaded LCS-NPs were prepared using dry film hydration and ionotropic gelation methods, respectively. The LCS-NP complex was prepared by mixing liposomes/NPs in a 2:1 (w/w) ratio. The cytotoxic effects of the various concentrations of insulin and formulation components on the pancreatic cell line were determined using a 3-(4,5-dimethyldiazol-2-yl)-2,5 diphenyl tetrazolium bromide assay and quantities to be used in the formulation were determined. Particle size, zeta potential, encapsulation efficiency, release profile and release kinetics, and transport properties of the prepared complex were investigated.
The newly developed insulin-loaded LCS-NP complex had a particle size of 2.85±0.035 μm and zeta potential of 8.11±1.025 mV. The encapsulation yield was found as 48±1.1%. insulin release from the complex was 80.9±2.71%. Insulin transport from β Tc cells was 30.50%. Permeability coefficients (log k) were calculated as -1.280±0.070 for the insulin solution and -1.020±0.062 for the insulin-loaded complex.
This study suggests that insulin could be successfully loaded into the newly developed LCS-NP complex, and it is thought that this complex carries an effective formulation potential for long-term efficacy in the treatment of diabetes.
近年来,由于在全球糖尿病治疗快速增长的背景下,不可或缺的肽结构胰岛素的肠胃外给药存在局限性,口服使用的研究迅速增加。本研究的目的是研究一种新型载胰岛素LCS-NP复合物的开发,及其对负责胰岛素释放的胰腺细胞的表征和功效。
分别采用干膜水化法和离子凝胶法制备空白脂质体和载胰岛素LCS-NP。通过以2:1(w/w)的比例混合脂质体/NP来制备LCS-NP复合物。使用3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四氮唑测定法测定不同浓度的胰岛素和制剂成分对胰腺细胞系的细胞毒性作用,并确定制剂中使用的量。研究了所制备复合物的粒径、zeta电位、包封效率、释放曲线和释放动力学以及转运性质。
新开发的载胰岛素LCS-NP复合物的粒径为2.85±0.035μm,zeta电位为8.11±1.025mV。包封率为48±1.1%。复合物的胰岛素释放率为80.9±2.71%。β Tc细胞的胰岛素转运率为30.50%。胰岛素溶液的渗透系数(log k)计算为-1.280±0.070,载胰岛素复合物的渗透系数为-1.020±0.062。
本研究表明胰岛素可以成功负载到新开发的LCS-NP复合物中,并且认为该复合物在糖尿病治疗中具有长期疗效的有效制剂潜力。